四类暴露难治性骨髓瘤与短生存期相关
这项回顾性单中心研究分析了45例对蛋白酶体抑制剂、免疫调节药物、抗CD38单抗和靶向BCMA治疗均失败的复发多发性骨髓瘤患者,从抗BCMA治疗失败起算,中位无进展生存期为4.4个月(95% CI=2.4-12.5),中位总生存期为6.3个月(95% CI=3.9-14.4),预后不良,存在未满足的医疗需求。
要点
- 四类暴露难治性骨髓瘤患者从抗BCMA失败起中位PFS为4.4个月,中位OS为6.3个月。
- 45例中7例(16%)接受抗体药物偶联物,20例(44%)接受双特异性抗体,18例(40%)接受CAR-T细胞治疗。
- 30例(67%)接受了至少1线后续治疗。
核心结论
- 四类暴露难治性骨髓瘤患者预后不良,从抗BCMA治疗失败起中位PFS为4.4个月,中位OS为6.3个月,仍存在未满足的医疗需求。
研究设计与样本
- 回顾性单中心研究,纳入45例对蛋白酶体抑制剂、免疫调节药物、抗CD38单抗和靶向BCMA治疗均失败的复发多发性骨髓瘤患者(四类暴露难治)。
主要发现
- 从抗BCMA治疗失败起,中位无进展生存期为4.4个月(95% CI=2.4-12.5),中位总生存期为6.3个月(95% CI=3.9-14.4)。
- 45例患者中,7例(16%)接受抗体药物偶联物,20例(44%)接受双特异性抗体,18例(40%)接受CAR-T细胞治疗。
- 30例(67%)接受了至少1线后续治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients. Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4-12.5) and OS 6.3 months (95% CI = 3.9-14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
引用
- Piron B, Costes-Tertrais D, Gastinne T, et al. Quad-class exposed/refractory myeloma is associated with short survival. Br J Haematol. 2023. PMID: 37833834. doi:10.1111/bjh.19148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。